Callio Therapeutics
Updated: January 09, 2026
CEO - Piers Ingram
Country: Singapore | Funding: $187M (+)
Founded: 2024
Website: https://calliotx.com/
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
Founded: 2024
Website: https://calliotx.com/
Callio Therapeutics develops next-generation antibody-drug conjugates (ADCs) with multiple payloads. They feature differentiated payload and linker technologies, which enables targeted delivery of drug combinations to tumor cells to maximize therapeutic effects for cancer patients. The company's flagship program is an ADC targeting HER2 breast cancer. Callio is a spinoff of Singapore-based Hummingbird Bioscience, which shares the CEO with Callio.
